Trade-Ideas: Agios Pharmaceuticals (AGIO) Is Today's New Lifetime High Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Agios Pharmaceuticals ( AGIO) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Agios Pharmaceuticals as such a stock due to the following factors:

  • AGIO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $41.3 million.
  • AGIO has traded 21,236 shares today.
  • AGIO is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AGIO with the Ticky from Trade-Ideas. See the FREE profile for AGIO NOW at Trade-Ideas

More details on AGIO:

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. AGIO has a PE ratio of 32.0. Currently there are 2 analysts that rate Agios Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Agios Pharmaceuticals has been 368,000 shares per day over the past 30 days. Agios has a market cap of $1.7 billion and is part of the health care sector and drugs industry. Shares are up 109.8% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

These 4 Healthcare Charts Are Signaling Buys

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Analysts' Actions -- Chipotle, Disney, Brinker, JPMorgan and More